View Older Stories View More Recent Stories
-
Ainos Achieves Major Breakthrough: Japan Patent Approval for VELDONA Redefines Antiviral Innovation
-
Water Tower Research Spotlights Ainos' AI Nose Programs and Strategic Milestones for 2025
-
Ainos (AIMD) Granted Nasdaq Extension to Regain Compliance
-
Ainos Granted 180-Day Extension by Nasdaq to Regain Compliance With Minimum Bid Price Rule
-
Ainos Unveils AI Nose for Robotics: Invites Global Robotics Companies to Join Forces in Shaping the Future of Smell-Enabled Robots
-
Ainos (AIMD) Files for 6.74M Share Offering by Selling Stockholders
-
CORRECTION BY SOURCE: Smell the Future: Ainos Elevates Health and Technology With AI Nose and VELDONA
-
Smell the Future: Ainos Elevates Health and Technology With AI Nose and VELDONA
-
Ainos Joins Webull Corporate Connect Service Platform to Enhance Investor Engagement
-
Water Tower Research Underscores Ainos' Partnership With Taiwan Tanabe Seiyaku for VELDONA Manufacturing and Marketing
-
Ainos, Inc. Announces Strategic Partnership with Taiwan Tanabe Seiyaku to Advance Manufacturing and Taiwan Market Promotion of Sjögren's Syndrome Drug
-
Water Tower Research Highlights IRB Approval for the Ainos VELDONA Clinical Sjogren's Trial Alongside 3Q24 Earnings and Developments
-
Ainos Announces IRB Approval for Sjögren’s Syndrome Clinical Study at Shuang Ho Hospital, Affiliated with Taipei Medical University, and Plans to Initiate New Phase of Treatment Evaluation in Q1 20
-
Ainos (AIMD) Takes Decisive Action to Protect Stockholder Interests and Combat Potential Illegal Trading Activities
-
Ainos Takes Decisive Action to Protect Stockholder Interests and Combat Potential Illegal Trading Activities
-
Ainos Reports Third Quarter 2024 Financial Results
-
Ainos Expands Patent Portfolio With Strategic Shareholder’s Cutting-Edge Technology Assets
-
Ainos Highlights VELDONA Clinical Advancements and Market Potential in Water Tower Research Spotlight Podcast
-
Ainos Advances Healthcare and Industrial Innovations with AI Nose and VELDONA Technologies
-
Ainos (AIMD) Receives IRB Approval From National Taiwan University Hospital for HIV-Oral Warts Clinical Trial
-
Ainos, Inc. Receives IRB Approval From National Taiwan University Hospital for HIV-Oral Warts Clinical Trial, Highlighting Value of FDA-Designated Orphan Drug VELDONA
-
Ainos Spotlighted in Water Tower Research Report on VELDONA Clinical Study for Sjogren’s Syndrome
-
Ainos (AIMD) Announced Plan to Initiate Taiwan Clinical Study of VELDONA for Treating Sjögren's Syndrome, a Rare Disease With Limited Treatment Options
-
Ainos Announced Plan to Initiate Taiwan Clinical Study of VELDONA for Treating Sjögren's Syndrome, a Rare Disease With Limited Treatment Options
-
Water Tower Research Highlights Ainos VELDONA Clinical Trial for HIV+ Patients with Oral Warts
-
Ainos (AIMD) to Initiate Taiwan Clinical Study for VELDONA
-
Ainos Announced Plan to Initiate Taiwan Clinical Study for VELDONA as Potential Treatment of Oral Warts in HIV-Seropositive Patients, an Orphan Drug Designated by the FDA
-
Ainos (AIMD) Secures Taiwan Invention Patent and Advances Global Patent Protection for VELDONA, a Breakthrough in Coronavirus Treatment and Prevention
-
Ainos Secures Taiwan Invention Patent and Advances Global Patent Protection for VELDONA, a Breakthrough in Coronavirus Treatment and Prevention
-
Ainos to Participate in H.C. Wainwright 26th Annual Global Investment Conference
-
Ainos CEO Highlights AI Nose Achievements and Upcoming 2H 2024 Milestones in Shareholder Letter
-
Ainos (AIMD) Unveils AI Nose Breakthrough that Revolutionizes Smart Manufacturing Factory Automation and Manufacturing Safety
-
Ainos Unveils AI Nose Breakthrough that Revolutionizes Smart Manufacturing Factory Automation and Manufacturing Safety
-
Ainos to Participate in Fireside Chat with Water Tower Research on August 22, 2024
-
Ainos (AIMD) Secures Exclusive Multi-Regions Invention Patent Licenses from Strategic Partner to Bolster AI Nose and Point-Of-Care Testing
-
Ainos Secures Exclusive Multi-Regions Invention Patent Licenses from Strategic Partner to Bolster AI Nose and Point-Of-Care Testing
-
Ainos Concludes Growth Financing From Lind Partners
-
Ainos Reports Second Quarter 2024 Financial Results
-
Ainos Enrolls First Subject for Clinical Study of VELDONA-Based Animal FCGS Drug
-
Ainos (AIMD) Unveils Critical Progress in Ainos Flora Clinical Trials and Next-Gen Plans Powered by NVIDIA CUDA
-
Ainos Unveils Critical Progress in Ainos Flora Clinical Trials and Next-Gen Plans Powered by NVIDIA CUDA
